Berti is an environmental impact investment company. They invest in innovative, growing, entrepreneurial businesses in the UK whose strategy focuses on reducing carbon emissions.

Berti Investments

JamJar Investments is a venture capital firm that invest in high growth consumer brand businesses in both digital and non-tech. Its combination of operational, commercial and brand experience was honed over 14 years taking innocent from scratch to sale to Coca Cola for north of half a billion £. That journey means the company understand the journey of entrepreneurs, the highs the lows, the challenges and some of the solutions.  JamJar is the consumer Venture Capital fund run by the innocent drinks founders.

JamJar Investments

A biotech merchant bank and investment firm

Mediqventures

Bicycle Day Ventures is an angel group that invests in the Psychedelic Future.

Bicycle Day Ventures

Oryx Ventures is a venture capital firm that focuses on investing in growth stage technology companies based out of the USA.

Oryx Ventures

BossaNova is the number one Brazilian Micro Venture Capital. We are the most active investor in the pre-seed stage in Latin America with more than 1200 investments in over 1000 Startups. We also invest in global companies, directly or through co-investment syndicates on AngelList.

Bossanova Investimentos

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%.   The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..

Adage Capital Management

FJ Labs is a stage-agnostic investment firm that focuses on marketplaces and consumer-facing startups. Their investments are seed and series A. The investment range of the company is $50,000 to $5,000,000. It invests in Alibaba Group, Beepi, BrightRoll, Betterment, Adore Me, and Earnest.

FJ Labs

Prime Movers Lab is a venture capital firm that seeks to invest in startups reinventing energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.

Prime Movers Lab

Delphi is dedicated to supporting the next generation of World-Positive founders with support, advice, and capital. Delphi invests in early-stage and late-stage companies and teams that hold promise to transform old-line industries with new, sustainable solutions.

Delphi VC

What If Ventures invests in stigmatized verticals within the healthcare market. For too long, stigma has artificially suppressed demand for care in indications such as mental health, fertility, and many others.  Societal changes are creating markets where stigma once stood in the way of people getting the care they need. The firm was founded in 2019 by Stephen Hays, after his own personal struggles with mental health and addiction fueled his desire to see more funding for solutions in that space.  Since then, the firm has broadened its aperture and has deployed nearly $80mm into more than 60 disruptive healthcare startups.

What If Ventures

Razor Capital is a venture capital and investment management firm with a focus on frontier markets. The firm invests and provides advisory services to entrepreneurs and early stage growth companies. Run by a cross-continent, multidisciplinary team Razor Capital strives to implement industry best practices to its portfolio companies.

Razor Capital

The future of mental wellness is being built today. Through its diversified investment fund, Palo Santo is positioned to increase the supply of clinically effective, affordable, and accessible mental health and addiction treatment solutions needed in today’s world. Supported by a rapidly growing body of evidence and strong FDA support, psychedelic-assisted treatments represent a paradigm shift in mental health care. Yet the emerging ecosystem of business opportunities is highly fragmented and, with a lack of institutional capital available, Palo Santo is targeting high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams. These businesses are positioned to have a profound impact on treating conditions such as depression, PTSD, anxiety, OCD, drug and alcohol dependence, chronic pain, Alzheimer’s, and a range of inflammatory-related illnesses.

Palo Santo Fund

Psymed Ventures is an investment syndicate that invests in early-stage psychedelics companies. The firm was founded in 2020 by Matias Serebrinsky and Dina Burkitbayeva and is headquartered in San Francisco, California, United States.

PsyMed Ventures

The Catalytic Impact Foundation accelerates breakthroughs — championing extraordinary innovations, catalytic ideas, and, most importantly, visionary leaders. The Foundation aims to solve complex problems and accelerate innovations, alleviate human suffering, address inequities, and improve the quality of human life through disruptive and scalable projects in the life sciences, education, inclusive entrepreneurship and global sustainability. The Foundation is a registered 501(c)(3) charitable organization incorporated in New York State.

THE CATALYTIC IMPACT FOUNDATION (CIF)

Negev Capital is a psychedelic medical intervention investment fund with assets of USD$21+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, and therapeutic use of psychedelic interventions for neuropsychiatric disorders; as well as those who have excellent management and science teams, and robust IP.  Negev believes that psychedelic medications will be not only disruptive to the practice of psychiatry but hold the potential to reduce enormous amounts of human suffering, and is committed to helping the field mature, and further promote ways for these treatments to reach all of those in need.

Negev Capital

Leafy Tunnel invests in addressing mental health and pain disorders, providing relief from pain, physical, and mental stress whilst improving life for both patients and their families.

Leafy Tunnel

Ayuh Ventures is an early stage fund investing in startups focused on neuroscience to address longevity, and aging

Ayuh Ventures

Beckley Psytech

Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assist individuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need.

<div>UK-based Beckley Psytech is developing a pipeline of psychedelic compounds to eventually create licensed pharmaceutical medicines for neurological and psychiatric disorders including short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment-resistant depression (TRD) and other rare and more common conditions. Its current research is focused on well-characterized psychedelic agents such as psilocybin, but it plans on developing other under researched psychedelic agents as well as new improved versions of existing psychedelics.&nbsp;&nbsp;</div>

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

<div>
 
 UK-based Beckley Psytech is developing a pipeline of psychedelic compounds to eventually create licensed pharmaceutical medicines for neurological and psychiatric disorders including short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment-resistant depression (TRD) and other rare and more common conditions. Its current research is focused on well-characterized psychedelic agents such as psilocybin, but it plans on developing other under researched psychedelic agents as well as new improved versions of existing psychedelics.&nbsp;&nbsp;
 
 
 The company is currently conducting a Phase 1b trial with low-dose psilocybin to treat SUNHA, and plans to initiate Phase 1 trial with a novel formulation of intranasal 5-MeO-DMT for treatment-resistant depression (TRD).&nbsp;
 
 
 Funding and financials
 
 
 Beckley Psytech was formed in 2019, out of Beckley Foundation, a well-established think tank in psychedelic research. In 
 <a href="https://sp-edge.com/updates/25190">
 January 2024
 </a>
 , the company raised USD 50 million in strategic investment from Atai Life Sciences. The new funds were allocated towards speeding up the development of Beckley Psytech&rsquo;s clinical-stage, patent-protected psychedelic candidates, BPL-003 and ELE-101.
 
</div>

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies conducting research on psychedelic compounds and developing novel therapeutics.

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

<div>
 
 UK psychedelic research firm Beckley Psytech received a USD 50 million strategic investment from clinical-stage biopharmaceutical company atai Life Sciences. This comprises USD 40 million in direct investment and USD 10 million in secondary share purchases, giving atai a 35.5% stake in Beckley Psytech.
 This funding aims to accelerate the development of Beckley Psytech's clinical-stage, patent-protected psychedelic candidates BPL-003 and ELE-101. These substances will be added to atai’s mental health innovation platform. Clinical trials data for both candidates is due by 2024.
</div>

Beckley Psytech

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless